Absolute Bioavailability of Reslizumab in Healthy Subjects
Completed · Phase 1
Conditions studied: Absolute Bioavailability
In brief
The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants
Key facts
- Study ID
- NCT01990443
- Run by
- Teva Branded Pharmaceutical Products R&D, Inc.
- People needed
- 75
- Starts
- 2013-06-01
- Expected to finish
- 2014-03-01
- Last updated by the study team
- 2014-03-31
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Teva Investigational Site 10567 — Anaheim, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.